Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 멀틸란 에이.쥐.filedCritical원본미기재
Priority to KR1019890006419ApriorityCriticalpatent/KR900000081A/en
Publication of KR900000081ApublicationCriticalpatent/KR900000081A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
내용 없음No content
Description
트리암테렌의 약학적 액제Triamterene Pharmaceutical Solution
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
Claims (10)
약학적으로 유효한 양의 트리암테렌, 글리콜, 젖산 또는 젖산염, 전술한 글리콜과 젖산 또는 젖산염은 트리암테렌을 액제로 유지하는데 충분한 양을 함유하는 트리암테렌의 약학적 액제.A pharmaceutically effective amount of triamterene, glycol, lactic acid or lactic acid, the aforementioned glycol and lactic acid or lactate contain a sufficient amount of triamterene to maintain triamterene in a liquid.약학적으로 허용되는 희석제를 포함하는 특허청구 범위 제1항의 약학적 액제.The pharmaceutical solution of claim 1 comprising a pharmaceutically acceptable diluent.트리암테렌을 약0.5mg/ml-약100mg/ml함유한 특허청구 범위 제1항 및 제2항의 약학적 액제.The pharmaceutical solution of claims 1 and 2 containing about 0.5 mg / ml to about 100 mg / ml of triamterene.글리콜이 푸로필렌글리콜이며 폴리에틸렌 글리콜 또는 그의 혼합물의 용량이 약1%-약50%의 범위내에서 존재하는 특허청구 범위 제1항 및 제2항의 약학적 액제.The pharmaceutical solution of claims 1 and 2 wherein the glycol is furopylene glycol and the dose of polyethylene glycol or mixtures thereof is within the range of about 1% to about 50%.희석제로서 글리세린을 함유하는 특허청구 범위 제2항의 약학적 액제.The pharmaceutical solution of claim 2 containing glycerin as a diluent.젖산이 약0.1%-약20%이 범위내에서 존재하는 특허청구 범위 제1항 및 제2항의 약학적 액제.The pharmaceutical solution of claim 1 wherein the lactic acid is present in the range of about 0.1% to about 20%.트리암테렌이 약 5mg/ml-약100mg/ml의 범위내에서 존재하고 젖산 또는 젖산염은 트리암테렌 매 5mg/ml에 대해서 약1%이상 함유하며 분자량이 약200-약6,000인 글리콜의 유효량을 함유하고 본 용액이 pH 약4-약6을 가지며 약학적으로 허용되는 희석제를 함유하는 경구투여를 위한 트리암테렌의 약학적 액제인 이뇨제.Triamterene is present in the range of about 5 mg / ml to about 100 mg / ml, and lactic acid or lactic acid contains about 1% or more of every 5 mg / ml of triamterene and has an effective amount of glycol having a molecular weight of about 200 to about 6,000. A diuretic, which is a pharmaceutical solution of triamterene for oral administration, wherein the solution has a pH of about 4 to about 6 and contains a pharmaceutically acceptable diluent.트리아메테렌, 히드로클로로치자이드, 글리콜, 젖산 또는 젖산염을 함유하고 전술한 글리콜과 젖산 또는 젖산염은 트리암테렌을 용액으로 유지하는데 충분한 양으로 존재하며 약학적으로 허용되는 희석제를 함유하는 이뇨제 및 혈압강하제인 약학적 액제.Diuretics and blood pressure containing triameterene, hydrochlorochizide, glycols, lactic acid or lactic acid and the aforementioned glycols and lactic acid or lactic acid are present in an amount sufficient to maintain triamterene in solution and contain a pharmaceutically acceptable diluent Pharmaceutical solution that is a lowering agent.트리암테렌이 약 0.5mg/ml-약100mg/ml의 범위내에서 존재하며 히드로클로로치아자이드는 약0.25mg/ml-약50mg/ml의 범위내에서 존재하는 특허청구범위 제8항에 따른 이뇨제 및 혈압강하제인 약학적 액제.The diuretic according to claim 8, wherein triamterene is present in the range of about 0.5 mg / ml to about 100 mg / ml and hydrochlorothiazide is present in the range of about 0.25 mg / ml to about 50 mg / ml. And pharmaceutical solutions which are hypotensive agents.희석제로서 글리세린을 함유하며 그의 용량이 약20%-약55%범위내에서 존재하는 이뇨제이며 혈압강하제인 특허청구범위 제8항의 약학적 액제.The pharmaceutical solution of claim 8 which contains glycerin as a diluent and whose dose is present in the range of about 20% to about 55% and is a blood pressure lowering agent.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
Novel pharmaceutical composition for the preparation of a stable powder containing an active ingredient comprising a combination of acetylsalicylic acid and metoclopramide